Prostate Cancer is the most frequently diagnosed cancer and the second leading cause of death among men in Western countries.
The MovemberFoundation’s ultimate goal is to reach a day where no man dies of this disease. This year's campaign 'STOP MEN DYING TOO YOUNG' aimed at making a difference for men's health – in prostate cancer, testicular cancer, mental health and suicide prevention. You can still donate!
Food for Thought - Detection of Prostate Cancer in Urine
To successfully cure patients with prostate cancer it is important to detect the disease in an early stage and identify aggressive cancers that need treatment. Many studies have shown the feasibility of urine for the non-invasive detection of Prostate Cancer. Manipulation of the prostate increases the release of biomarkers such as prostate cancer cells, RNAs, DNAs, proteins and other small molecules into the first-voided urine. To make sure the patient collects first-void urine only, a user-friendly Colli-Pee device can be used. Today four Urinary Biomarkers tests are commercially available and many more are under development (Fujita et al, 2018).
Novosanis reached a new major milestone
Colli-Pee an award-winning, CE-labelled & FDA-listed device to capture first-void urine just got granted its European patent. This compact, user-friendly device can be used by all genders and is suited for postal delivery. Collection of first-void urine allows for improved detection of biomarkers for early stage diagnosis and monitoring of (urological) cancers as well as sexually transmitted infections including Human Papilloma Virus (HPV), a virus able to cause HPV related cancers such as cervical-, anal-, orpharyngeal cancer.
Meet us some of the upcoming events we love to talk business & science:
- EUROGIN December 2-5, 2018, Lisbon, Portugal
- ECCMID, ISUTI, Uronomics, ASCO and/or ESMO